Neng Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Neng Wang has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Zhiyu Wang
State Key Laboratory of Traditional Chinese Medicine Syndrome, Chinese Medicine Guangdong Laboratory, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine
10 shared publications Bowen Yang
State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
5 shared publicationsShengqi Wang
State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
5 shared publicationsJuping Zhang
State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
4 shared publicationsXuan Wang
State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
4 shared publicationsYifeng Zheng
State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
4 shared publications
Latest Publications
- Open Access
- 11 February 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1788538
Editorial: Role of ncRNAs in immunogenic cell death of cancer
Cancer remains a complex, heterogeneous disease, constituting a major global health burden. While advances in surgery, radiotherapy, chemotherapy, and targeted therapies have reshaped clinical practice, enduring challenges such as recurrence, metastasis, and drug resistance continue to impede curative outcomes. In recent years, immunotherapylargely driven by immune checkpoint inhibitors (ICIs)has introduced a paradigm shift in cancer treatment. Nevertheless, its efficacy is still limited to a subset of patients, making the improvement of response rates and long-term efficacy a central focus of contemporary research. Within this context, ICD has emerged as a promising therapeutic frontier (Galluzzi et al., 2020). By triggering the release of damage-associated molecular patterns (DAMPs) through distinct molecular mechanisms, ICD converts dying tumor cells into potent inducers of adaptive immune activation (Kroemer et al., 2022).Parallel advances in non-coding RNA (ncRNA) research have unveiled a new dimension for deciphering the complexity of biological regulation. Once considered as "genomic dark matter", molecules such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) are now recognized as key regulators within intricate transcriptional and posttranscriptional networks (Anastasiadou et al., 2018), with a profound influence on processes such as cell fate determination and immune microenvironment modulation (Kumar et al., 2023). A single ncRNA can often modulate hundreds of downstream targets, establishing these molecules as potential "molecular hubs" for intervening in ICD-associated pathways and reshaping the tumor immune microenvironment. However, research on ICD-associated ncRNAs currently faces several critical gaps, including a lack of systematic screening, unclear regulatory hierarchies and interaction networks among different ncRNA types, and unrealized potential for clinical translation as biomarkers or therapeutic targets.This research topic focuses on the "ncRNA -ICDtumor immunity" regulatory axis, addressing a central scientific question: How do ICD-related ncRNAs precisely regulate cancer progression? It delineates how miRNAs rapidly orchestrate ICD, how lncRNAs epigenetically regulate its potential, and how circRNAs mediate ICD transmission by acting as miRNA sponges (Bremnes et al., 2016) . The collected studies analyze the pivotal role of ncRNAs within the ICDtumor immunity axis from three distinct perspectives (Figure 1). In the sections that follow, we will elaborate on these findings based on the six articles included in this column.Firstly, ncRNAs constitute the core regulatory hub of the ICD signaling network, and the articles in this column systematically reveal how they execute this pivotal function to precisely regulate cancer progression through mechanistic insight, functional expansion, and clinical validation. Fang et al. 1 elucidated that diverse ncRNAs acted as precision tuners of ICD by directly modulating core pathways such as endoplasmic reticulum stress and ROS production, thereby determining the strength and specificity of immunogenic signals and providing a mechanistic framework for understanding miRNAmediated modulation and circRNA sponging effects. Furthermore, Ju et al. 2 revealed that lncRNAs could epigenetically regulate ferroptosisa cell death modality sharing overlapping pathways with 3 ICDthereby expanding the scope and depth of ncRNA-mediated immunogenic stress responses and underscoring their functional diversity and synergy. The clinical significance of these foundational mechanisms is concretely demonstrated by Yan et al. 3 Their large-scale meta-analysis established a robust association between ICD-driven immune infiltration and cancer patient prognosis, thereby completing the critical translational link from ncRNA-regulated molecular events to clinically observable anti-tumor immunity.Secondly, exosomal ncRNAs serve as key mediators in disseminating the immune effects of ICD and the reprogramming of the tumor microenvironment. This column examined how ncRNAs extend beyond cell-autonomous regulation by leveraging extracellular vesicles for intercellular communication, thereby systemically disseminating ICD-induced immune responses. Duan et al. 4demonstrated that tumor-derived exosomal ncRNAs (e.g., miRNAs, circRNAs) functioned as active signaling mediators that reprogrammed the tumor microenvironment and remotely modulated immune or stromal cell activity. These findings provided essential spatiotemporal and mechanistic context for processes such as circRNA-mediated miRNA sponging in ICD transmission, illustrating how ncRNAs serve as systemic amplifiers that convert local ICD events into broad antitumor immunity.Thirdly, targeting ICD-associated ncRNAs, despite challenges such as model limitations and tumor heterogeneity, has emerged as a promising new paradigm for cancer immunotherapy. Addressing this therapeutic direction, the column provided in-depth discussions at the conceptual, methodological, and critical levels. Sun et al. 5 explicitly proposed and substantiated this strategy, which builds precisely on the earlier elucidated mechanisms of ncRNA-mediated fine-tuning, aiming to enhance ICD and thus improve immunotherapy outcomes by modulating specific miRNA, lncRNA, or circRNA networks. To advance the translation of this paradigm, Hu et al. 6 highlighted the unique strengths of the zebrafish model for real-time, ex vivo functional studies of ncRNAs and drug screening, offering an innovative tool to address tumor heterogeneity and dynamically evaluate ncRNA-targeting interventions. Collectively, however, these articles also pointed to persistent challenges, including the need for more precise disease models to validate targets and the necessity of overcoming tumor heterogeneity to enable ncRNA-stratified precision intervention. These considerations outline critical pathways for translating...
- 11 February 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1788538
Open AccessEditorial: Role of ncRNAs in immunogenic cell death of cancer
Cancer remains a complex, heterogeneous disease, constituting a major global health burden. While advances in surgery, radiotherapy, chemotherapy, and targeted therapies have reshaped clinical practice, enduring challenges such as recurrence, metastasis, and drug resistance continue to impede curative outcomes. In recent years, immunotherapylargely driven by immune checkpoint inhibitors (ICIs)has introduced a paradigm shift in cancer treatment. Nevertheless, its efficacy is still limited to a subset of patients, making the improvement of response rates and long-term efficacy a central focus of contemporary research. Within this context, ICD has emerged as a promising therapeutic frontier (Galluzzi et al., 2020). By triggering the release of damage-associated molecular patterns (DAMPs) through distinct molecular mechanisms, ICD converts dying tumor cells into potent inducers of adaptive immune activation (Kroemer et al., 2022).Parallel advances in non-coding RNA (ncRNA) research have unveiled a new dimension for deciphering the complexity of biological regulation. Once considered as "genomic dark matter", molecules such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) are now recognized as key regulators within intricate transcriptional and posttranscriptional networks (Anastasiadou et al., 2018), with a profound influence on processes such as cell fate determination and immune microenvironment modulation (Kumar et al., 2023). A single ncRNA can often modulate hundreds of downstream targets, establishing these molecules as potential "molecular hubs" for intervening in ICD-associated pathways and reshaping the tumor immune microenvironment. However, research on ICD-associated ncRNAs currently faces several critical gaps, including a lack of systematic screening, unclear regulatory hierarchies and interaction networks among different ncRNA types, and unrealized potential for clinical translation as biomarkers or therapeutic targets.This research topic focuses on the "ncRNA -ICDtumor immunity" regulatory axis, addressing a central scientific question: How do ICD-related ncRNAs precisely regulate cancer progression? It delineates how miRNAs rapidly orchestrate ICD, how lncRNAs epigenetically regulate its potential, and how circRNAs mediate ICD transmission by acting as miRNA sponges (Bremnes et al., 2016) . The collected studies analyze the pivotal role of ncRNAs within the ICDtumor immunity axis from three distinct perspectives (Figure 1). In the sections that follow, we will elaborate on these findings based on the six articles included in this column.Firstly, ncRNAs constitute the core regulatory hub of the ICD signaling network, and the articles in this column systematically reveal how they execute this pivotal function to precisely regulate cancer progression through mechanistic insight, functional expansion, and clinical validation. Fang et al. 1 elucidated that diverse ncRNAs acted as precision tuners of ICD by directly modulating core pathways such as endoplasmic reticulum stress and ROS production, thereby determining the strength and specificity of immunogenic signals and providing a mechanistic framework for understanding miRNAmediated modulation and circRNA sponging effects. Furthermore, Ju et al. 2 revealed that lncRNAs could epigenetically regulate ferroptosisa cell death modality sharing overlapping pathways with 3 ICDthereby expanding the scope and depth of ncRNA-mediated immunogenic stress responses and underscoring their functional diversity and synergy. The clinical significance of these foundational mechanisms is concretely demonstrated by Yan et al. 3 Their large-scale meta-analysis established a robust association between ICD-driven immune infiltration and cancer patient prognosis, thereby completing the critical translational link from ncRNA-regulated molecular events to clinically observable anti-tumor immunity.Secondly, exosomal ncRNAs serve as key mediators in disseminating the immune effects of ICD and the reprogramming of the tumor microenvironment. This column examined how ncRNAs extend beyond cell-autonomous regulation by leveraging extracellular vesicles for intercellular communication, thereby systemically disseminating ICD-induced immune responses. Duan et al. 4demonstrated that tumor-derived exosomal ncRNAs (e.g., miRNAs, circRNAs) functioned as active signaling mediators that reprogrammed the tumor microenvironment and remotely modulated immune or stromal cell activity. These findings provided essential spatiotemporal and mechanistic context for processes such as circRNA-mediated miRNA sponging in ICD transmission, illustrating how ncRNAs serve as systemic amplifiers that convert local ICD events into broad antitumor immunity.Thirdly, targeting ICD-associated ncRNAs, despite challenges such as model limitations and tumor heterogeneity, has emerged as a promising new paradigm for cancer immunotherapy. Addressing this therapeutic direction, the column provided in-depth discussions at the conceptual, methodological, and critical levels. Sun et al. 5 explicitly proposed and substantiated this strategy, which builds precisely on the earlier elucidated mechanisms of ncRNA-mediated fine-tuning, aiming to enhance ICD and thus improve immunotherapy outcomes by modulating specific miRNA, lncRNA, or circRNA networks. To advance the translation of this paradigm, Hu et al. 6 highlighted the unique strengths of the zebrafish model for real-time, ex vivo functional studies of ncRNAs and drug screening, offering an innovative tool to address tumor heterogeneity and dynamically evaluate ncRNA-targeting interventions. Collectively, however, these articles also pointed to persistent challenges, including the need for more precise disease models to validate targets and the necessity of overcoming tumor heterogeneity to enable ncRNA-stratified precision intervention. These considerations outline critical pathways for translating...
- Open Access
- 1 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 8
Chronic Psychological Stress Activates TRP/TAM/CXCL1 Signaling to Promote Breast Cancer Adipocyte Lipolysis via KEAP1 m 6 A Demethylation
Chronic unpredicted mild stress (CUMS) and obesity are well-known risk factors for breast cancer (BC). However, their underlying correlation and potential mechanisms remain unknown. Herein, CUMS was found to promote BC growth and metastasis with increased adipocyte lipolysis, reactive oxygen species (ROS) burst, and mitochondrial fission. Metabolomic analysis identified tryptophan (TRP) as the main responding metabolite, which markedly induced macrophage M2 polarization and CXCL1 expression, and in turn promoted adipocyte lipolysis. Molecular investigation showed that CXCL1 triggered KEAP1 m 6 A demethylation via FTO (fat mass and obesity-associated protein) up-regulation, subsequently reducing NRF2 expression to exacerbate ROS burst and mitochondrial fission. Furthermore, either siCXCL1 or FTO inhibition markedly inhibited CUMS-induced BC progression, accompanied by suppression of adipocyte lipolysis, ROS production, and mitochondrial fission, as well as KEAP1 m 6 A demethylation. Our findings highlight the novel signaling of TRP/TAM/CXCL1 in mediating adipocyte lipolysis underlying CUMS-induced BC progression, and KEAP1 m 6 A demethylation presents a promising therapeutic target.
- 1 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 8
Open AccessChronic Psychological Stress Activates TRP/TAM/CXCL1 Signaling to Promote Breast Cancer Adipocyte Lipolysis via KEAP1 m 6 A Demethylation
Chronic unpredicted mild stress (CUMS) and obesity are well-known risk factors for breast cancer (BC). However, their underlying correlation and potential mechanisms remain unknown. Herein, CUMS was found to promote BC growth and metastasis with increased adipocyte lipolysis, reactive oxygen species (ROS) burst, and mitochondrial fission. Metabolomic analysis identified tryptophan (TRP) as the main responding metabolite, which markedly induced macrophage M2 polarization and CXCL1 expression, and in turn promoted adipocyte lipolysis. Molecular investigation showed that CXCL1 triggered KEAP1 m 6 A demethylation via FTO (fat mass and obesity-associated protein) up-regulation, subsequently reducing NRF2 expression to exacerbate ROS burst and mitochondrial fission. Furthermore, either siCXCL1 or FTO inhibition markedly inhibited CUMS-induced BC progression, accompanied by suppression of adipocyte lipolysis, ROS production, and mitochondrial fission, as well as KEAP1 m 6 A demethylation. Our findings highlight the novel signaling of TRP/TAM/CXCL1 in mediating adipocyte lipolysis underlying CUMS-induced BC progression, and KEAP1 m 6 A demethylation presents a promising therapeutic target.
- Open Access
- 8 November 2023
- Published by EDP Sciences in BIO Web of Conferences
- Vol. 72, 02008
Dietary Compound Diosmetin Chemosensitizes Breast Cancer Stem Cells by Suppressing HMGB1-mediated Autophagy
Breast cancer stem cells (CSCs) are a small cluster of highly tumorigenic cell subsets with self-renewal and multi-directional differentiation potential. Accumulating studies have shown that CSCs lead to chemotherapy resistance and recurrence of breast cancer, which is the main reason for the failure of chemotherapy in breast cancer. Autophagy is one of the key mechanisms to protect tumor cells from chemotherapeutic stimulation and other stresses, which contributes to the ultimate survival of CSCs in refractory or recurrent tumors. This study was carried out in terms of multiple strategies such as flow cytometry, stem-like detection, zebrafish tumor xenograft model construction, autophagy lentivirus construction, and western blotting analysis to prove that a natural flavonoid compound diosmetin safely and effectively promoted the tumor-killing effect of chemotherapeutic drug for breast cancer. The involved mechanism was closely related to its ability to reduce HMGB1 expression and subsequently block the autophagy pathway of breast CSCs. This study will provide new ideas and tools for the development of breast cancer drug resistance mechanism and targeted drugs.
- 8 November 2023
- Published by EDP Sciences in BIO Web of Conferences
- Vol. 72, 02008
Open AccessDietary Compound Diosmetin Chemosensitizes Breast Cancer Stem Cells by Suppressing HMGB1-mediated Autophagy
Breast cancer stem cells (CSCs) are a small cluster of highly tumorigenic cell subsets with self-renewal and multi-directional differentiation potential. Accumulating studies have shown that CSCs lead to chemotherapy resistance and recurrence of breast cancer, which is the main reason for the failure of chemotherapy in breast cancer. Autophagy is one of the key mechanisms to protect tumor cells from chemotherapeutic stimulation and other stresses, which contributes to the ultimate survival of CSCs in refractory or recurrent tumors. This study was carried out in terms of multiple strategies such as flow cytometry, stem-like detection, zebrafish tumor xenograft model construction, autophagy lentivirus construction, and western blotting analysis to prove that a natural flavonoid compound diosmetin safely and effectively promoted the tumor-killing effect of chemotherapeutic drug for breast cancer. The involved mechanism was closely related to its ability to reduce HMGB1 expression and subsequently block the autophagy pathway of breast CSCs. This study will provide new ideas and tools for the development of breast cancer drug resistance mechanism and targeted drugs.
- Open Access
- 19 September 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1147189
Integrative dissection of 5-hydroxytryptamine receptors-related signature in the prognosis and immune microenvironment of breast cancer
Background: Depression increases the risk of breast cancer recurrence and metastasis. However, there lacks potential biomarkers for predicting prognosis in breast cancer. 5-hydroxytryptamine (5-HT) plays a key role in the pathogenesis and treatment of depression. In this study, we developed a prognostic signature based on 5-HT receptors (5-HTRs) and elucidated its potential immune regulatory mechanisms for breast cancer prognosis.Methods: Oncomine, GEPIA, UALCAN, cBioPortal, Kaplan-Meier plotter, and TIMER were used to analyze differential expression, prognostic value, genetic alteration, and immune cell infiltration of HTRs in breast cancer patients. The model training and validation assays were based on the analyses of GSE1456 and GSE86166. A risk signature was established by univariate and multivariate Cox regression analyses. The transwell assay was utilized to verify the effect of the 5-HTRs expression on breast cancer invasion. Effects of HTR2A/2B inhibitor on CD8+ T cell proliferation and infiltration as well as apoptosis of 4T1 cells in the tumor microenvironment were detected by flow cytometry and TUNEL assay. Zebrafish and mouse breast cancer xenografts were used to determine the effect of HTR2A/2B inhibitor on breast cancer metastasis.Results: The expression levels of HTR1A, HTR1B, HTR2A, HTR2B, HTR2C, HTR4, and HTR7 were significantly downregulated in highly malignant breast cancer types. 5-HTRs were significantly associated with recurrence-free survival (RFS) in breast cancer patients. The genetic alteration of HTR1D, HTR3A, HTR3B, and HTR6 in breast cancer patients was significantly associated with shorter overall survival (OS). Finally, HTR2A and HTR2B were determined to construct the risk signature. The expression of HTR2A/2B was positively correlated with the infiltration of immune cells such as CD8+ T cells and macrophages. Furthermore, inhibition of HTR2A expression could suppress CD8+ T cell proliferation and enhance invasion and metastasis of breast cancer cells in both zebrafish and mice model.Conclusions: The HTR2A/2B risk signature not only highlights the significance of HTRs in breast cancer prognosis by modulating cancer immune microenvironment, but also provides a novel gene-testing tool for early prevention of depression in breast cancer patients and lead to an improved prognosis and quality of life.
- 19 September 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1147189
Open AccessIntegrative dissection of 5-hydroxytryptamine receptors-related signature in the prognosis and immune microenvironment of breast cancer
Background: Depression increases the risk of breast cancer recurrence and metastasis. However, there lacks potential biomarkers for predicting prognosis in breast cancer. 5-hydroxytryptamine (5-HT) plays a key role in the pathogenesis and treatment of depression. In this study, we developed a prognostic signature based on 5-HT receptors (5-HTRs) and elucidated its potential immune regulatory mechanisms for breast cancer prognosis.Methods: Oncomine, GEPIA, UALCAN, cBioPortal, Kaplan-Meier plotter, and TIMER were used to analyze differential expression, prognostic value, genetic alteration, and immune cell infiltration of HTRs in breast cancer patients. The model training and validation assays were based on the analyses of GSE1456 and GSE86166. A risk signature was established by univariate and multivariate Cox regression analyses. The transwell assay was utilized to verify the effect of the 5-HTRs expression on breast cancer invasion. Effects of HTR2A/2B inhibitor on CD8+ T cell proliferation and infiltration as well as apoptosis of 4T1 cells in the tumor microenvironment were detected by flow cytometry and TUNEL assay. Zebrafish and mouse breast cancer xenografts were used to determine the effect of HTR2A/2B inhibitor on breast cancer metastasis.Results: The expression levels of HTR1A, HTR1B, HTR2A, HTR2B, HTR2C, HTR4, and HTR7 were significantly downregulated in highly malignant breast cancer types. 5-HTRs were significantly associated with recurrence-free survival (RFS) in breast cancer patients. The genetic alteration of HTR1D, HTR3A, HTR3B, and HTR6 in breast cancer patients was significantly associated with shorter overall survival (OS). Finally, HTR2A and HTR2B were determined to construct the risk signature. The expression of HTR2A/2B was positively correlated with the infiltration of immune cells such as CD8+ T cells and macrophages. Furthermore, inhibition of HTR2A expression could suppress CD8+ T cell proliferation and enhance invasion and metastasis of breast cancer cells in both zebrafish and mice model.Conclusions: The HTR2A/2B risk signature not only highlights the significance of HTRs in breast cancer prognosis by modulating cancer immune microenvironment, but also provides a novel gene-testing tool for early prevention of depression in breast cancer patients and lead to an improved prognosis and quality of life.
- Open Access
- 20 May 2023
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 42 (1) , 1-21
Chronic psychological stress promotes breast cancer pre-metastatic niche formation by mobilizing splenic MDSCs via TAM/CXCL1 signaling
Background: Emerging studies have identified chronic psychological stress as an independent risk factor influencing breast cancer growth and metastasis. However, the effects of chronic psychological stress on pre-metastatic niche (PMN) formation and the underlying immunological mechanisms remain largely unknown. Methods: The effects and molecular mechanisms of chronic unpredictable mild stress (CUMS) on modulating tumor-associated macrophages (TAMs) and PMN formation were clarified by multiplex immunofluorescence technique, cytokine array, chromatin immunoprecipitation, the dual-luciferase reporter assay, and breast cancer xenografts. Transwell and CD8+ T cytotoxicity detection were used to analyze the mobilization and function of myeloid-derived suppressor cells (MDSCs). mCherry-labeled tracing strategy and bone marrow transplantation were applied to explore the crucial role of splenic CXCR2+/+ MDSCs facilitating PMN formation under CUMS. Results: CUMS significantly promoted breast cancer growth and metastasis, accompanied by TAMs accumulation in the microenvironment. CXCL1 was identified as a crucial chemokine in TAMs facilitating PMN formation in a glucocorticoid receptor (GR)-dependent manner. Interestingly, the spleen index was significantly reduced under CUMS, and splenic MDSCs were validated as a key factor mediating CXCL1-induced PMN formation. The molecular mechanism study revealed that TAM-derived CXCL1 enhanced the proliferation, migration, and anti-CD8+ T cell functions of MDSCs via CXCR2. Moreover, CXCR2 knockout and CXCR2−/−MDSCs transplantation significantly impaired CUMS-mediated MDSC elevation, PMN formation, and breast cancer metastasis. Conclusion: Our findings shed new light on the association between chronic psychological stress and splenic MDSC mobilization, and suggest that stress-related glucocorticoid elevation can enhance TAM/CXCL1 signaling and subsequently recruit splenic MDSCs to promote PMN formation via CXCR2. Graphical
- 20 May 2023
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 42 (1) , 1-21
Open AccessChronic psychological stress promotes breast cancer pre-metastatic niche formation by mobilizing splenic MDSCs via TAM/CXCL1 signaling
Background: Emerging studies have identified chronic psychological stress as an independent risk factor influencing breast cancer growth and metastasis. However, the effects of chronic psychological stress on pre-metastatic niche (PMN) formation and the underlying immunological mechanisms remain largely unknown. Methods: The effects and molecular mechanisms of chronic unpredictable mild stress (CUMS) on modulating tumor-associated macrophages (TAMs) and PMN formation were clarified by multiplex immunofluorescence technique, cytokine array, chromatin immunoprecipitation, the dual-luciferase reporter assay, and breast cancer xenografts. Transwell and CD8+ T cytotoxicity detection were used to analyze the mobilization and function of myeloid-derived suppressor cells (MDSCs). mCherry-labeled tracing strategy and bone marrow transplantation were applied to explore the crucial role of splenic CXCR2+/+ MDSCs facilitating PMN formation under CUMS. Results: CUMS significantly promoted breast cancer growth and metastasis, accompanied by TAMs accumulation in the microenvironment. CXCL1 was identified as a crucial chemokine in TAMs facilitating PMN formation in a glucocorticoid receptor (GR)-dependent manner. Interestingly, the spleen index was significantly reduced under CUMS, and splenic MDSCs were validated as a key factor mediating CXCL1-induced PMN formation. The molecular mechanism study revealed that TAM-derived CXCL1 enhanced the proliferation, migration, and anti-CD8+ T cell functions of MDSCs via CXCR2. Moreover, CXCR2 knockout and CXCR2−/−MDSCs transplantation significantly impaired CUMS-mediated MDSC elevation, PMN formation, and breast cancer metastasis. Conclusion: Our findings shed new light on the association between chronic psychological stress and splenic MDSC mobilization, and suggest that stress-related glucocorticoid elevation can enhance TAM/CXCL1 signaling and subsequently recruit splenic MDSCs to promote PMN formation via CXCR2. Graphical
- Open Access
- 15 February 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 809565
Corrigendum: Autophagy Blockade by Ai Du Qing Formula Promotes Chemosensitivity of Breast Cancer Stem Cells Via GRP78/β-Catenin/ABCG2 Axis
Corrigendum: Autophagy Blockade by Ai Du Qing Formula Promotes Chemosensitivity of Breast Cancer Stem Cells Via GRP78/β-Catenin/ABCG2 Axis
- 15 February 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 809565
Open AccessCorrigendum: Autophagy Blockade by Ai Du Qing Formula Promotes Chemosensitivity of Breast Cancer Stem Cells Via GRP78/β-Catenin/ABCG2 Axis
Corrigendum: Autophagy Blockade by Ai Du Qing Formula Promotes Chemosensitivity of Breast Cancer Stem Cells Via GRP78/β-Catenin/ABCG2 Axis
- 1 September 2021
- Published by Elsevier in Phytomedicine
- Vol. 90, 153628
Aiduqing formula suppresses breast cancer metastasis via inhibiting CXCL1-mediated autophagy
- 1 September 2021
- Published by Elsevier in Phytomedicine
- Vol. 90, 153628
Aiduqing formula suppresses breast cancer metastasis via inhibiting CXCL1-mediated autophagy
- Open Access
- 8 June 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Autophagic Inhibition of Caveolin-1 by Compound Phyllanthus urinaria L. Activates Ubiquitination and Proteasome Degradation of β-catenin to Suppress Metastasis of Hepatitis B-Associated Hepatocellular Carcinoma
Compound Phyllanthus urinaria L. (CP) is a traditional Chinese medicine (TCM) formula for cancer treatment in the clinic, particularly during progression of hepatitis B-associated hepatocellular carcinoma (HBV-associated HCC). Nevertheless, its anti-metastatic action and mechanisms are not well elucidated. In this study, CP was found to exert remarkable inhibitory effects on the proliferation, migration and invasion of HBV-associated HCC cells. The following network and biological analyses predicted that CP mainly targeted Caveolin-1 (Cav-1) to induce anti-metastatic effects, and Wnt/β-catenin pathway was one of the core mechanisms of CP action against HBV-associated HCC. Further experimental validation implied that Cav-1 overexpression promoted metastasis of HBV-associated HCC by stabilizing β-catenin, while CP administration induced autophagic degradation of Cav-1, activated the Akt/GSK3β-mediated proteasome degradation of β-catenin via ubiquitination activation, and subsequently attenuated the metastasis-promoting effect of Cav-1. In addition, the anti-cancer and anti-metastatic action of CP was further confirmed by in vivo and ex vivo experiments. It was found that CP inhibited the tumor growth and metastasis of HBV-associated HCC in both mice liver cancer xenograft and zebrafish xenotransplantation models. Taken together, our study not only highlights the novel function of CP formula in suppressing metastasis of HBV-associated HCC, but it also addresses the critical role of Cav-1 in mediating Akt/GSK3β/β-catenin axis to control the late-phase of cancer progression.
- 8 June 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Open AccessAutophagic Inhibition of Caveolin-1 by Compound Phyllanthus urinaria L. Activates Ubiquitination and Proteasome Degradation of β-catenin to Suppress Metastasis of Hepatitis B-Associated Hepatocellular Carcinoma
Compound Phyllanthus urinaria L. (CP) is a traditional Chinese medicine (TCM) formula for cancer treatment in the clinic, particularly during progression of hepatitis B-associated hepatocellular carcinoma (HBV-associated HCC). Nevertheless, its anti-metastatic action and mechanisms are not well elucidated. In this study, CP was found to exert remarkable inhibitory effects on the proliferation, migration and invasion of HBV-associated HCC cells. The following network and biological analyses predicted that CP mainly targeted Caveolin-1 (Cav-1) to induce anti-metastatic effects, and Wnt/β-catenin pathway was one of the core mechanisms of CP action against HBV-associated HCC. Further experimental validation implied that Cav-1 overexpression promoted metastasis of HBV-associated HCC by stabilizing β-catenin, while CP administration induced autophagic degradation of Cav-1, activated the Akt/GSK3β-mediated proteasome degradation of β-catenin via ubiquitination activation, and subsequently attenuated the metastasis-promoting effect of Cav-1. In addition, the anti-cancer and anti-metastatic action of CP was further confirmed by in vivo and ex vivo experiments. It was found that CP inhibited the tumor growth and metastasis of HBV-associated HCC in both mice liver cancer xenograft and zebrafish xenotransplantation models. Taken together, our study not only highlights the novel function of CP formula in suppressing metastasis of HBV-associated HCC, but it also addresses the critical role of Cav-1 in mediating Akt/GSK3β/β-catenin axis to control the late-phase of cancer progression.
- Open Access
- 3 June 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Autophagy Blockade by Ai Du Qing Formula Promotes Chemosensitivity of Breast Cancer Stem Cells Via GRP78/β-Catenin/ABCG2 Axis
Accumulating evidence suggests that the root of drug chemoresistance in breast cancer is tightly associated with subpopulations of cancer stem cells (CSCs), whose activation is largely dependent on taxol-promoting autophagy. Our pilot study identified GRP78 as a specific marker for chemoresistance potential of breast CSCs by regulating Wnt/β-catenin signaling. Ai Du Qing (ADQ) is a traditional Chinese medicine formula that has been utilized in the treatment cancer, particularly during the consolidation phase. In the present study, we investigated the regulatory effects and molecular mechanisms of ADQ in promoting autophagy-related breast cancer chemosensitivity. ADQ with taxol decreasing the cell proliferation and colony formation of breast cancer cells, which was accompanied by suppressed breast CSC ratio, limited self-renewal capability, as well as attenuated multi-differentiation. Furthermore, autophagy in ADQ-treated breast CSCs was blocked by taxol via regulation of β-catenin/ABCG2 signaling. We also validated that autophagy suppression and chemosensitizing activity of this formula was GRP78-dependent. In addition, GRP78 overexpression promoted autophagy-inducing chemoresistance in breast cancer cells by stabilizing β-catenin, while ADQ treatment downregulated GRP78, activated the Akt/GSK3β-mediated proteasome degradation of β-catenin via ubiquitination activation, and consequently attenuated the chemoresistance-promoted effect of GRP78. In addition, both mouse breast cancer xenograft and zebrafish xenotransplantation models demonstrated that ADQ inhibited mammary tumor growth, and the breast CSC subpopulation showed obscure adverse effects. Collectively, this study not only reveals the chemosensitizating mechanism of ADQ in breast CSCs, but also highlights the importance of GRP78 in mediating autophagy-promoting drug resistance via β-catenin/ABCG2 signaling.
- 3 June 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Open AccessAutophagy Blockade by Ai Du Qing Formula Promotes Chemosensitivity of Breast Cancer Stem Cells Via GRP78/β-Catenin/ABCG2 Axis
Accumulating evidence suggests that the root of drug chemoresistance in breast cancer is tightly associated with subpopulations of cancer stem cells (CSCs), whose activation is largely dependent on taxol-promoting autophagy. Our pilot study identified GRP78 as a specific marker for chemoresistance potential of breast CSCs by regulating Wnt/β-catenin signaling. Ai Du Qing (ADQ) is a traditional Chinese medicine formula that has been utilized in the treatment cancer, particularly during the consolidation phase. In the present study, we investigated the regulatory effects and molecular mechanisms of ADQ in promoting autophagy-related breast cancer chemosensitivity. ADQ with taxol decreasing the cell proliferation and colony formation of breast cancer cells, which was accompanied by suppressed breast CSC ratio, limited self-renewal capability, as well as attenuated multi-differentiation. Furthermore, autophagy in ADQ-treated breast CSCs was blocked by taxol via regulation of β-catenin/ABCG2 signaling. We also validated that autophagy suppression and chemosensitizing activity of this formula was GRP78-dependent. In addition, GRP78 overexpression promoted autophagy-inducing chemoresistance in breast cancer cells by stabilizing β-catenin, while ADQ treatment downregulated GRP78, activated the Akt/GSK3β-mediated proteasome degradation of β-catenin via ubiquitination activation, and consequently attenuated the chemoresistance-promoted effect of GRP78. In addition, both mouse breast cancer xenograft and zebrafish xenotransplantation models demonstrated that ADQ inhibited mammary tumor growth, and the breast CSC subpopulation showed obscure adverse effects. Collectively, this study not only reveals the chemosensitizating mechanism of ADQ in breast CSCs, but also highlights the importance of GRP78 in mediating autophagy-promoting drug resistance via β-catenin/ABCG2 signaling.
- Open Access
- 2 December 2017
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 36 (1) , 1-19
Direct inhibition of ACTN4 by ellagic acid limits breast cancer metastasis via regulation of β-catenin stabilization in cancer stem cells
Background: Pharmacology-based target identification has become a novel strategy leading to the discovery of novel pathological biomarkers. Ellagic acid (EA), a dietary polyphenol compound, exhibits potent anticancer activities; however, the underlying mechanisms remain unclear. The current study sought to determine the role and regulation of ACTN4 expression in human breast cancer metastasis and EA-based therapy. Methods: The anti-metastasis ability of EA was validated by MMTV-PyMT mice and in vitro cell models. Drug affinity responsive target stability (DARTS) was utilized to identify ACTN4 as the direct target of EA. The metastatic regulated function of ACTN4 were assessed by cancer stem cells (CSCs)-related assays, including mammosphere formation, tumorigenic ability, reattachment differentiation, and signaling pathway analysis. The mechanisms of ACTN4 on β-catenin stabilization were investigated by western blotting, co-immunoprecipitation and ubiquitination assays. The clinical significance of ACTN4 was based on human tissue microarray (TMA) analysis and The Cancer Genome Atlas (TCGA) database exploration. Results: EA inhibited breast cancer growth and metastasis via directly targeting ACTN4 in vitro and in vivo, and was accompanied by a limited CSC population. ACTN4 knockdown resulted in the blockage of malignant cell proliferation, colony formation, and ameliorated metastasis potency. ACTN4-positive CSCs exhibited a higher ESA+ proportion, increased mammosphere-formation ability, and enhanced in vivo tumorigenesis ability. Mechanism exploration revealed that interruption of ACTN4/β-catenin interaction will result in the activation of β-catenin proteasome degradation. Increased ACTN4 expression was directly associated with the advanced cancer stage, an increased incidence of metastasis, and poor overall survival period. Conclusions: Taken together, our results suggest that ACTN4 plays an important role in breast CSCs-related metastasis and is a novel therapeutic target of EA treatment.
- 2 December 2017
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 36 (1) , 1-19
Open AccessDirect inhibition of ACTN4 by ellagic acid limits breast cancer metastasis via regulation of β-catenin stabilization in cancer stem cells
Background: Pharmacology-based target identification has become a novel strategy leading to the discovery of novel pathological biomarkers. Ellagic acid (EA), a dietary polyphenol compound, exhibits potent anticancer activities; however, the underlying mechanisms remain unclear. The current study sought to determine the role and regulation of ACTN4 expression in human breast cancer metastasis and EA-based therapy. Methods: The anti-metastasis ability of EA was validated by MMTV-PyMT mice and in vitro cell models. Drug affinity responsive target stability (DARTS) was utilized to identify ACTN4 as the direct target of EA. The metastatic regulated function of ACTN4 were assessed by cancer stem cells (CSCs)-related assays, including mammosphere formation, tumorigenic ability, reattachment differentiation, and signaling pathway analysis. The mechanisms of ACTN4 on β-catenin stabilization were investigated by western blotting, co-immunoprecipitation and ubiquitination assays. The clinical significance of ACTN4 was based on human tissue microarray (TMA) analysis and The Cancer Genome Atlas (TCGA) database exploration. Results: EA inhibited breast cancer growth and metastasis via directly targeting ACTN4 in vitro and in vivo, and was accompanied by a limited CSC population. ACTN4 knockdown resulted in the blockage of malignant cell proliferation, colony formation, and ameliorated metastasis potency. ACTN4-positive CSCs exhibited a higher ESA+ proportion, increased mammosphere-formation ability, and enhanced in vivo tumorigenesis ability. Mechanism exploration revealed that interruption of ACTN4/β-catenin interaction will result in the activation of β-catenin proteasome degradation. Increased ACTN4 expression was directly associated with the advanced cancer stage, an increased incidence of metastasis, and poor overall survival period. Conclusions: Taken together, our results suggest that ACTN4 plays an important role in breast CSCs-related metastasis and is a novel therapeutic target of EA treatment.